

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2021 (including the 22nd WHO Model List of Essential Medicines and the 8th WHO Model List of Essential Medicines for Children)



The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world.

To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO *Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

To purchase WHO publications, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland; email: bookorders@who.int; order on line: <http://apps.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 3 5

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2021 (including the 22nd WHO Model List of Essential Medicines and the 8th WHO Model List of Essential Medicines for Children)

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2021 (including the 22nd WHO Model List of Essential Medicines and the 8th WHO Model List of Essential Medicines for Children).

(WHO Technical Report Series, No. 1035)

ISBN 978-92-4-004113-4 (electronic version)

ISBN 978-92-4-004114-1 (print version)

ISSN 0512-3054

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2021 (including the 22nd WHO Model List of Essential Medicines and the 8th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1035). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Layout by Interligar

Contents

Executive summary	vii
List of participants	xli
Declaration of interests for Expert Committee members and temporary advisers	xliv
1. Introduction	1
2. Open session	3
3. General items	5
4. Summary of recommendations	13
5. Applications for the 22nd Model List of Essential Medicines and the 8th Model List of Essential Medicines for Children	20
Section 4: ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS	20
4.2 Specific	20
N-acetylcysteine – addition – EML and EMLc	20
Section 5: ANTICONVULSANTS/ANTIEPILEPTICS	28
Valproic acid (sodium valproate) – change to listing – EML and EMLc	28
Section 6: ANTI-INFECTIVE MEDICINES	33
6.1 Anthelmintics	33
Albendazole, mebendazole, praziquantel – new indication – EML and EMLc	33
6.2 Antibacterials	43
Antibiotics for bronchitis and bronchiolitis – new indication – EML and EMLc	43
Antibiotics for ocular infections – new indications – EML and EMLc	48
Antibiotics for necrotizing fasciitis – new indication – EML and EMLc	56
Antibiotics for neonatal meningitis – new indication – EMLc	61
Antibiotics for intra-abdominal infections in children – new indication – EMLc	67
Amoxicillin – remove indication – EML and EMLc	71
Amoxicillin + clavulanic acid – new formulation – EML	74
Cefalexin – change indication – EML and EMLc	81
Ceftazidime + avibactam – addition - EML	84
Antibiotics – new formulations – EML	95
Moxifloxacin and rifapentine – new indication – EML	99
Pyrazinamide – new formulation – EML and EMLc	104
Rifapentine – new formulation – EML and EMLc	108
Rifapentine + isoniazid – new formulation – EML and EMLc	117
Antituberculosis medicines – formulations for deletion – EML and EMLc	124
Antituberculosis medicines – new formulations – EML and EMLc	129
Bedaquiline – new formulation – EML and EMLc	135
Delamanid – new formulation – EMLc	141
6.3 Antifungal medicines	148
Echinocandin antifungals – addition – EML and EMLc	148
6.4 Antiviral medicines	165
Antiretrovirals – formulations for deletion – EML and EMLc	165

Dolutegravir – new formulation – EMLc	169
Abacavir + lamivudine + lopinavir/ritonavir – new formulation – EMLc	178
Oseltamivir – deletion – EML and EMLc	185
Glecaprevir + pibrentasvir – addition – EMLc	189
Daclatasvir and sofosbuvir – addition – EMLc	196
Sofosbuvir + velpatasvir – addition – EMLc	205
Section 7: ANTIMIGRAINE MEDICINES	212
7.1 For treatment of acute attack	212
Sumatriptan – addition – EML	212
Section 8: IMMUNOMODULATORS AND ANTINEOPLASTICS	221
8.1 Immunomodulators for non-malignant disease	221
Tacrolimus – addition – EML and EMLc	221
8.2 Antineoplastics and supportive medicines	236
Azacitidine – addition – EML	236
Cancer medicines for low-grade glioma – new indication – EML and EMLc	242
Cancer medicines for children – new indications – EML and EMLc	248
Cancer medicines for head and neck cancer – review – EML	255
Doxorubicin for rhabdomyosarcoma – review – EML and EMLc	262
Vinorelbine – new indication – EML and EMLc	267
BRAF/MEK inhibitors – addition – EML	272
Cyclin-dependent kinase (CDK) 4/6 inhibitors – addition – EML	283
Everolimus – addition – EML and EMLc	296
Ibrutinib – addition – EML	303
Imatinib – new indication – EML	312
Osimertinib – addition – EML	320
Pertuzumab – addition – EML	328
Zanubrutinib – addition for chronic lymphocytic leukaemia/small lymphocytic lymphoma – EML	340
Zanubrutinib – addition for mantle cell lymphoma – EML	347
PD-1/PD-L1 immune checkpoint inhibitors – addition – EML	353
Daratumumab – addition – EML	376
Tisnelizumab – addition for Hodgkin lymphoma – EML	388
Tisnelizumab – addition for urothelial cancer – EML	394
Enzalutamide – addition – EML	401
Fulvestrant – addition – EML	412
Rasburicase – addition – EML and EMLc	419
CAR-T cell therapy – review	427
Section 13: DERMATOLOGICAL MEDICINES	442
13.4 Medicines affecting skin differentiation and proliferation	442
Calcipotriol – addition – EML and EMLc	442
Section 15: DISINFECTANTS AND ANTISEPTICS	451
15.1 Antiseptics	451
15.2 Disinfectants	451
Hypochlorous acid – addition – EML and EMLc	451
Section 18: MEDICINES FOR ENDOCRINE DISORDERS	461
Simvastatin – new indication – EML	461
18.5 Medicines for diabetes	470
Long-acting insulin analogues – addition – EML and EMLc	470

Sodium-glucose cotransporter-2 (SGLT2) inhibitors – addition – EML	486
Section 19: IMMUNOLOGICALS	499
19.2 Sera, immunoglobulins and monoclonal antibodies	499
Anti-rabies virus monoclonal antibodies – addition – EML and EMLc	499
Equine rabies immunoglobulin – addition – EML and EMLc	507
Section 22: MEDICINES FOR REPRODUCTIVE HEALTH AND PERINATAL CARE	513
22.1 Contraceptives	513
Ethinylestradiol + etonogestrel – new formulation – EML	513
22.5 Other medicines administered to the mother	520
Multiple micronutrient supplement – addition – EML	520
Section 24: MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS	532
Methylphenidate – addition – EML and EMLc	532
24.1 Medicines used in psychotic disorders	543
Paliperidone and risperidone long-acting injection – addition – EML	543
24.5 Medicines for disorders due to psychoactive substance use	555
Bupropion – addition – EML	555
Varenicline – addition – EML	578
Section 29: MEDICINES FOR DISEASES OF JOINTS	601
29.2 Disease-modifying anti-rheumatic drugs (DMARDs)	601
Hydroxychloroquine – new indication – EML	601
29.3 Juvenile joint diseases	609
Anakinra – addition – EML and EMLc	609
Tocilizumab – addition – EML and EMLc	619
Triamcinolone – addition – EML and EMLc	632
Section 30: DENTAL PREPARATIONS	640
Fluoride toothpaste – addition – EML and EMLc	640
Glass ionomer cement – addition – EML and EMLc	651
Silver diamine fluoride – addition – EML and EMLc	660
Annex 1	
WHO Model List of Essential Medicines – 22nd List (2021)	667
Annex 2	
WHO Model List of Essential Medicines for Children – 8th List (2021)	755
Annex 3	
Alphabetical list of essential medicines (with ATC codes & section numbers)	813



预览已结束，完整报告链接

<https://www.yunbaogao.cn/report/index/re>